NanoViricides, Inc. (NNVC)

US — Healthcare Sector
Peers: VRCA  JSPR  SABS  GBIO  EVAX  IGC  QTTB  MAIA  ANTX  TENX 

Automate Your Wheel Strategy on NNVC

With Tiblio's Option Bot, you can configure your own wheel strategy including NNVC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NNVC
  • Rev/Share 0.0
  • Book/Share 420014.8695
  • PB 0.0
  • Debt/Equity 0.0
  • CurrentRatio 1.0594
  • ROIC -0.2504

 

  • MktCap 22335535.0
  • FreeCF/Share -98242.4713
  • PFCF -0.0
  • PE -0.0
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.9952

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation NNVC Alliance Global Partners -- Buy -- -- Dec. 16, 2025

News

NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
NNVC
Published: February 19, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is planning to accelerate its development pipeline, focusing on MPox treatment in Central Africa, viral acute respiratory infections, and a potential pediatric RSV indication.

Read More
image for news NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
NNVC
Published: February 11, 2025 by: Proactive Investors
Sentiment: Positive

NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to remain effective against the H5N1 virus, even as the virus undergoes rapid mutations.

Read More
image for news NanoViricides announces readiness to combat bird flu with antiviral drug NV-387

About NanoViricides, Inc. (NNVC)

  • IPO Date 2005-10-26
  • Website https://www.nanoviricides.com
  • Industry Biotechnology
  • CEO Anil R. Diwan
  • Employees 7
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.